Kimberly-Clark to Acquire Kenvue in $48.7 Billion Deal
Kimberly-Clark has agreed to acquire Kenvue, the maker of Tylenol, Band-Aid, and Benadryl, in a $48.7 billion cash-and-stock transaction.
The deal will unite some of the world's best-known consumer health and personal care brands, positioning the combined company as a global powerhouse in the consumer staples sector.
- Shares of Kenvue jumped 15% in early trading following the announcement.
- Kimberly-Clark stock fell 12% as investors weighed the scale of the purchase.
The merger, approved by both companies' boards, is expected to close in the second half of 2026, pending regulatory and shareholder approval.
Kenvue shareholders will receive $3.50 in cash and 0.14625 Kimberly-Clark shares for each Kenvue share held, amounting to approximately $21.01 per share based on Kimberly-Clark's Oct.
Author's summary: Kimberly-Clark acquires Kenvue for $48.7 billion.
More News
- Finding the Magic: Reflections from PHM 2025 - The Hospitalist
- PFCU Credit Union Honors Veterans Day with Flag Retirement Initiative
- More Iowans turn to food pantries after missing SNAP payments
- MP says cuts have 'stripped young people of support'
- Building Donor Communities for New or Underfunded Issues (SSIR)